$ECOR I SEE DIS electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
income statement | balance sheet | cash flow annual | quarterly
Period End Date TTM 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Period Length 12 Months 12 Months 12 Months 12 Months 12 Months
Total Revenue
3.24 2.39 0.99
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more.
Learn more
Cost of Revenue
1.31 1.16 0.58
Gross Profit
1.93 1.23 0.41
Selling, General and Administrative
23.69 35.42 42.50
Research and Development
4.81 9.90 12.47
Unusual Expense/Income
0.46 2.00 0.00
Total Operating Expense
30.27 48.48 55.55
Operating Income
-27.03 -46.09 -54.55
Interest Income Net
0.20 0.97 1.01
Other Income Net
-0.01 -0.01 -2.22
Net Income Before Taxes
-26.84 -45.13 -55.76
Provision for Income Taxes
-1.15 0.02 0.00
Net Income
-25.69 -45.15 -55.82
Income Avail. to Common Excl. Extraord.
-25.69 -45.15 -55.82
Income Avail. to Common Incl. Extraord.
-25.69 -45.15 -55.82
Diluted Average Shares
34.99 29.38 29.26
Diluted EPS Excl. Extraord.
-0.78660 -1.53669 -1.90761
Diluted EPS Incl. Extraord.
-0.78660 -1.53669 -1.90761
